Ets1 suppresses atopic dermatitis by suppressing pathogenic T cell responses

Area of Science:

• Immunology
• Dermatology
• Genetics

Background:

• Atopic dermatitis (AD) is a complex inflammatory skin disease involving adaptive and innate immune cells.
• CD4+ T helper (Th) cells, particularly Th2, Th17, and Th22 subsets, play significant roles in AD pathogenesis.
• The precise molecular mechanisms driving immune responses in AD remain incompletely understood.

Purpose of the Study:

• To investigate the role of the atopic dermatitis susceptibility gene Ets1 in AD pathogenesis.
• To identify Ets1 target genes and binding partners to elucidate its function.
• To assess the clinical relevance of Ets1 defects in disease severity in human and mouse models.

Main Methods:

• Analysis of ETS1 levels in severe AD patients and an experimental AD-like skin inflammation model.
• Generation and characterization of T cell-specific Ets1-deficient mice (Ets1ΔdLck).
• Investigation of gp130 expression and IL-6 signaling pathway activation in Ets1-deficient T cells.
• Evaluation of disease amelioration using a selective gp130 inhibitor (SC144).

Main Results:

• Reduced ETS1 levels correlated with severe AD in patients and mouse models.
• Ets1-deficient mice exhibited exacerbated AD-like symptoms and increased pathogenic Th cell responses.
• Ets1 deficiency led to increased T cell-intrinsic gp130 expression, activating the IL-6 signaling pathway.
• Inhibition of gp130 with SC144 significantly reduced disease severity and pathogenic Th cell responses.

Conclusions:

• Ets1 plays a protective role in restricting pathogenic T helper cell responses in atopic dermatitis.
• Increased gp130 expression and IL-6 signaling downstream of Ets1 deficiency contribute to AD pathogenesis.
• Targeting the gp130 pathway presents a potential therapeutic strategy for treating atopic dermatitis.